Drechsler Andrew T. - 12 May 2021 Form 4 Insider Report for Provention Bio, Inc.

Reporting relationship: Chief Financial Officer
Issuer ticker: N/A
Reported as of: 12 May 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 May 2021, 19:37:32 UTC
Next SEC filing: 17 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Andrew T Drechsler

Key filing fact

Drechsler Andrew T. filed Form 4 for Provention Bio, Inc. on 14 May 2021.

Key facts

This page summarizes Drechsler Andrew T.'s Form 4 filing for Provention Bio, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 May 2021, 19:37.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRVB transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +139,500
Change %
Price: $0.000000
Shares after: 139,500
Date: 12 May 2021
Ownership: Direct
Underlying class: Common Stock, par value $0.0001
Underlying amount: 139,500
Exercise price: $6.80
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

69,750 of the options granted will vest as follows: 25% will vest and become exercisable on May 12, 2022 and 75% will vest and become exercisable monthly over 36 months such that these options will be fully vested and exercisable on May 12, 2025. The remaining 69,750 of the options granted will vest and become exercisable, if at all, in three equal installments of 23,250 options, with each such installment triggered upon the achievement of one of three separate corporate performance milestones prior to or during the year 2024.

Footnote F2

The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan.